Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

Summary

This is a multicenter, open-label study to evaluate the safety, tolerability, and efficacy of 4% QRX003 lotion applied twice daily (BID) for 12 weeks to Netherton syndrome (NS) diseased skin in all affected areas of the body excluding the scalp (the Treatment Area), totaling approximately 50% Body Surface Area (BSA) or more.

Timeline

Start

2026-03-19

Primary completion

2027-01-31

Completion

2027-03-31

Drugs

Indications